Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2023 | Nov. 20, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Sep. 30, 2023 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2023 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-13789 | |
Entity Registrant Name | ADHERA THERAPEUTICS, INC. | |
Entity Central Index Key | 0000737207 | |
Entity Tax Identification Number | 11-2658569 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 8000 Innovation Parkway | |
Entity Address, City or Town | Baton Rouge | |
Entity Address, State or Province | LA | |
Entity Address, Postal Zip Code | 70820 | |
City Area Code | (919) | |
Local Phone Number | 518-3748 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 7,220,900 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
ASSETS | ||
Cash | $ 32,388 | $ 31,761 |
Prepaid expenses | 11,686 | 46,750 |
Total Current Assets | 44,074 | 78,511 |
Total Assets | 44,074 | 78,511 |
CURRENT LIABILITIES: | ||
Accounts payable | 2,351,653 | 2,396,716 |
Accrued expenses | 5,545,905 | 4,372,366 |
Accrued dividends | 578,333 | 498,453 |
Term loans, net of discounts | 9,660,355 | 7,332,978 |
Convertible notes payable | 1,168,765 | 1,251,696 |
Contract liabilities | 100,000 | |
Derivative liabilities | 6,892,612 | 6,386,284 |
Total Current Liabilities | 26,359,515 | 22,264,061 |
Total Liabilities | 26,359,515 | 22,264,061 |
Commitments and Contingencies (Note 9) | ||
STOCKHOLDERS’ DEFICIT: | ||
Common stock: $0.006 par value, 180,000,000 shares authorized; 5,168,912 and 3,160,877 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 31,014 | 18,938 |
Additional paid-in capital | 33,636,179 | 33,547,890 |
Treasury stock (5,594 shares, at cost) | (2,000) | (2,000) |
Accumulated deficit | (59,980,637) | (55,750,381) |
Total Stockholders’ Deficit | (26,315,441) | (22,185,550) |
Total Liabilities and Stockholders’ Deficit | 44,074 | 78,511 |
Series C Convertible Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT: | ||
Preferred stock: $0.01 par value; 100,000 authorized; | ||
Series D Convertible Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT: | ||
Preferred stock: $0.01 par value; 100,000 authorized; | ||
Series E Convertible Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT: | ||
Preferred stock: $0.01 par value; 100,000 authorized; | 3 | 3 |
Series F Convertible Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT: | ||
Preferred stock: $0.01 par value; 100,000 authorized; | ||
Series G Convertible Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT: | ||
Preferred stock: $0.01 par value; 100,000 authorized; | ||
Related Party [Member] | ||
CURRENT LIABILITIES: | ||
Due to related parties | $ 61,892 | $ 25,568 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares designated | 100,000 | 100,000 |
Common stock, par value | $ 0.006 | $ 0.006 |
Common stock, shares authorized | 180,000,000 | 180,000,000 |
Common stock, shares issued | 5,168,912 | 3,160,877 |
Common stock, shares outstanding | 5,168,912 | 3,160,877 |
Treasury stock, shares | 5,594 | 5,594 |
Series C Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares designated | 1,200 | 1,200 |
Preferred stock, shares issued | 100 | 100 |
Preferred stock, shares outstanding | 100 | 100 |
Preferred stock, liquidation preference value | $ 510,000 | $ 510,000 |
Series D Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares designated | 220 | 220 |
Preferred stock, shares issued | 40 | 40 |
Preferred stock, shares outstanding | 40 | 40 |
Preferred stock, liquidation preference value | $ 12,000 | $ 12,000 |
Series E Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares designated | 3,500 | 3,500 |
Preferred stock, shares issued | 267 | 267 |
Preferred stock, shares outstanding | 267 | 267 |
Preferred stock, liquidation preference value | $ 1,886,414 | $ 1,886,414 |
Series F Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares designated | 2,200 | 2,200 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Series G Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares designated | 6,000 | 6,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Statement [Abstract] | ||||
REVENUES, NET | ||||
OPERATING EXPENSES: | ||||
Professional fees | 83,267 | 169,166 | 339,972 | 521,861 |
Compensation expense | 143,238 | 154,161 | 429,396 | 304,161 |
General and administrative expenses | 42,992 | 224,243 | 148,153 | 430,268 |
Total Operating Expenses | 269,497 | 547,570 | 917,521 | 1,256,290 |
LOSS FROM OPERATIONS | (269,497) | (547,570) | (917,521) | (1,256,290) |
OTHER INCOME (EXPENSES): | ||||
Interest expense, net | (359,184) | (317,045) | (1,050,830) | (989,288) |
Amortization of debt discount | (245,839) | (777,082) | (1,245,825) | (1,265,419) |
Gain on debt extinguishment, net | 12,671 | 92,068 | 87,921 | 306,707 |
Loan inducement expense | (809,126) | |||
Derivative income (expense) | (2,673,966) | (253,723) | (214,994) | 1,425,494 |
Total Other Income (Expenses), net | (3,266,318) | (1,255,782) | (3,232,854) | (522,506) |
NET LOSS | (3,535,815) | (1,803,352) | (4,150,375) | (1,778,796) |
Accrued preferred stock dividends | (26,920) | (8,706) | (79,881) | (574,706) |
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ (3,562,735) | $ (1,812,058) | $ (4,230,256) | $ (2,353,502) |
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS: | ||||
Basic | $ (0.83) | $ (0.57) | $ (1.16) | $ (1.17) |
Diluted | $ (0.83) | $ (0.57) | $ (1.16) | $ (1.17) |
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||
Basic | 4,303,866 | 3,160,877 | 3,649,428 | 2,019,953 |
Diluted | 4,303,866 | 3,160,877 | 3,649,428 | 2,019,953 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) | Preferred Stock [Member] Series C Preferred Stock [Member] | Preferred Stock [Member] Series D Preferred Stock [Member] | Preferred Stock [Member] Series E Preferred Stock [Member] | Preferred Stock [Member] Series F Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Treasury Stock, Common [Member] | Retained Earnings [Member] | Total |
Balance at Dec. 31, 2021 | $ 33 | $ 3 | $ 5,124 | $ 27,905,994 | $ (53,016,772) | $ (25,105,618) | |||
Balance, shares at Dec. 31, 2021 | 100 | 40 | 3,326 | 358 | 853,946 | ||||
Accrued dividend | (364,166) | (364,166) | |||||||
Issuance of common stock for convertible note conversions | $ 76 | 27,908 | 27,984 | ||||||
Issuance of common stock for convertible note conversions, shares | 12,721 | ||||||||
Net Income (loss) | (73,730) | (73,730) | |||||||
Issuance of common stock with convertible notes | $ 75 | 17,905 | 17,980 | ||||||
Issuance of common stock with convertible notes, shares | 12,500 | ||||||||
Balance at Mar. 31, 2022 | $ 33 | $ 3 | $ 5,275 | 27,951,807 | (53,454,668) | (25,497,550) | |||
Balance, shares at Mar. 31, 2022 | 100 | 40 | 3,326 | 358 | 879,167 | ||||
Balance at Dec. 31, 2021 | $ 33 | $ 3 | $ 5,124 | 27,905,994 | (53,016,772) | (25,105,618) | |||
Balance, shares at Dec. 31, 2021 | 100 | 40 | 3,326 | 358 | 853,946 | ||||
Net Income (loss) | (1,778,796) | ||||||||
Balance at Sep. 30, 2022 | $ 3 | $ 19,001 | 33,547,832 | $ (2,000) | (55,370,274) | (21,805,438) | |||
Balance, shares at Sep. 30, 2022 | 100 | 40 | 267 | 3,166,831 | 5,954 | ||||
Balance at Mar. 31, 2022 | $ 33 | $ 3 | $ 5,275 | 27,951,807 | (53,454,668) | (25,497,550) | |||
Balance, shares at Mar. 31, 2022 | 100 | 40 | 3,326 | 358 | 879,167 | ||||
Accrued dividend | (201,834) | (201,834) | |||||||
Net Income (loss) | 98,286 | 98,286 | |||||||
Issuance of common stock with term loan | $ 115 | 11,705 | 11,820 | ||||||
Issuance of common stock with term loan, shares | 19,231 | ||||||||
Conversion of Series E Preferred to common stock | $ (30) | $ 12,212 | 5,044,457 | 5,056,639 | |||||
Conversion of Series E Preferred to common stock, shares | (3,059) | 2,035,306 | |||||||
Conversion of Series F Preferred to common stock | $ (3) | $ 1,399 | 539,863 | 541,259 | |||||
Conversion of Series F Preferred to common stock, shares | (358) | 233,127 | |||||||
Repurchase of common stock | $ (2,000) | (2,000) | |||||||
Repurchase of common stock, shares | 5,954 | ||||||||
Balance at Jun. 30, 2022 | $ 3 | $ 19,001 | 33,547,832 | $ (2,000) | (53,558,216) | (19,993,380) | |||
Balance, shares at Jun. 30, 2022 | 100 | 40 | 267 | 3,166,831 | 5,954 | ||||
Accrued dividend | (8,706) | (8,706) | |||||||
Net Income (loss) | (1,803,352) | (1,803,352) | |||||||
Balance at Sep. 30, 2022 | $ 3 | $ 19,001 | 33,547,832 | $ (2,000) | (55,370,274) | (21,805,438) | |||
Balance, shares at Sep. 30, 2022 | 100 | 40 | 267 | 3,166,831 | 5,954 | ||||
Balance at Dec. 31, 2022 | $ 3 | $ 18,938 | 33,547,890 | $ (2,000) | (55,750,381) | (22,185,550) | |||
Balance, shares at Dec. 31, 2022 | 100 | 40 | 267 | 3,160,877 | 5,954 | ||||
Accrued dividend | (26,334) | (26,334) | |||||||
Issuance of common stock for convertible note conversions | $ 107 | 4,893 | 5,000 | ||||||
Issuance of common stock for convertible note conversions, shares | 17,861 | ||||||||
Net Income (loss) | (885,839) | (885,839) | |||||||
Balance at Mar. 31, 2023 | $ 3 | $ 19,045 | 33,552,783 | $ (2,000) | (56,662,554) | (23,092,723) | |||
Balance, shares at Mar. 31, 2023 | 100 | 40 | 267 | 3,178,738 | 5,954 | ||||
Balance at Dec. 31, 2022 | $ 3 | $ 18,938 | 33,547,890 | $ (2,000) | (55,750,381) | $ (22,185,550) | |||
Balance, shares at Dec. 31, 2022 | 100 | 40 | 267 | 3,160,877 | 5,954 | ||||
Issuance of common stock for convertible note conversions, shares | 55,317,596 | ||||||||
Net Income (loss) | $ (4,150,375) | ||||||||
Balance at Sep. 30, 2023 | $ 3 | $ 31,014 | 33,636,179 | $ (2,000) | (59,980,637) | (26,315,441) | |||
Balance, shares at Sep. 30, 2023 | 100 | 40 | 267 | 5,168,912 | 5,954 | ||||
Balance at Mar. 31, 2023 | $ 3 | $ 19,045 | 33,552,783 | $ (2,000) | (56,662,554) | (23,092,723) | |||
Balance, shares at Mar. 31, 2023 | 100 | 40 | 267 | 3,178,738 | 5,954 | ||||
Accrued dividend | (26,627) | (26,627) | |||||||
Issuance of common stock for convertible note conversions | $ 3,964 | 56,883 | 60,847 | ||||||
Issuance of common stock for convertible note conversions, shares | 660,716 | ||||||||
Net Income (loss) | 271,279 | 271,279 | |||||||
Balance at Jun. 30, 2023 | $ 3 | $ 23,009 | 33,609,666 | $ (2,000) | (56,417,902) | (22,787,224) | |||
Balance, shares at Jun. 30, 2023 | 100 | 40 | 267 | 3,839,454 | 5,954 | ||||
Accrued dividend | (26,920) | (26,920) | |||||||
Issuance of common stock for convertible note conversions | $ 6,205 | 28,313 | 34,518 | ||||||
Issuance of common stock for convertible note conversions, shares | 1,029,458 | ||||||||
Net Income (loss) | (3,535,815) | (3,535,815) | |||||||
Issuance of common stock for cashless warrant exercises | $ 1,800 | (1,800) | |||||||
Issuance of common stock share for cashless warrant exercises | 300,000 | ||||||||
Issuance of common stock with convertible notes, shares | |||||||||
Balance at Sep. 30, 2023 | $ 3 | $ 31,014 | $ 33,636,179 | $ (2,000) | $ (59,980,637) | $ (26,315,441) | |||
Balance, shares at Sep. 30, 2023 | 100 | 40 | 267 | 5,168,912 | 5,954 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
Net loss | $ (3,535,815) | $ (885,839) | $ (1,803,352) | $ (73,730) | $ (4,150,375) | $ (1,778,796) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Gain on debt extinguishment | (12,671) | (92,068) | (87,921) | (306,707) | |||
Derivative expense (income) | 2,673,966 | 253,723 | 214,994 | (1,425,494) | |||
Amortization of debt discount and fees | 1,245,825 | 1,265,419 | |||||
Inducement expense | 809,126 | ||||||
Change in operating assets and liabilities: | |||||||
Prepaid expenses and other assets | 35,064 | (3,555) | |||||
Accounts payable | (8,739) | (38,167) | |||||
Accrued expenses | 1,186,871 | 931,338 | |||||
Contract liabilities | 100,000 | ||||||
NET CASH USED IN OPERATING ACTIVITIES | (655,155) | (1,355,962) | |||||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
Proceeds from notes payable | 788,900 | 2,000,000 | |||||
Proceeds from convertible notes payable | 200,000 | ||||||
Notes payable and convertible notes issuance costs | (42,300) | (327,800) | |||||
Repayment of convertible notes payable | (90,818) | (456,954) | |||||
Purchase of treasury stock | (2,000) | ||||||
NET CASH PROVIDED BY FINANCING ACTIVITIES | 655,782 | 1,413,246 | |||||
NET INCREASE IN CASH | 627 | 57,284 | |||||
CASH, beginning of the period | $ 31,761 | $ 76,104 | 31,761 | 76,104 | $ 76,104 | ||
CASH, end of the period | $ 32,388 | $ 133,388 | 32,388 | 133,388 | $ 31,761 | ||
Cash paid during the period for: | |||||||
Interest | 17,513 | 117,301 | |||||
Income taxes | |||||||
Non-cash investing and financing activities: | |||||||
Conversion of Series E to common stock | 5,056,635 | ||||||
Conversion of Series F to common stock | 541,258 | ||||||
Debt discounts for issuance costs, warrants and derivatives | 406,846 | 1,342,957 | |||||
Issuance of common stock for conversion of convertible notes and accrued interest | 72,774 | 9,922 | |||||
Accrued and deemed dividends | $ 79,881 | $ 574,705 |
ORGANIZATION AND BUSINESS OPERA
ORGANIZATION AND BUSINESS OPERATIONS | 9 Months Ended |
Sep. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
ORGANIZATION AND BUSINESS OPERATIONS | NOTE 1 – ORGANIZATION AND BUSINESS OPERATIONS Adhera Therapeutics, Inc. and its wholly-owned subsidiaries(collectively “Adhera,” “we”, or the “Company”), historically focused on drug development and commercialization of “small molecule” drugs to treat Parkinson’s disease (PD) and Type 1 diabetes. More recently, as it has struggled to operate with very limited working capital, it has been seeking to license a diabetes drug to a publicly-traded Nasdaq company as described in Note 9. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the nine months ended September 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries and eliminates any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. Going Concern and Management’s Liquidity Plans The accompanying unaudited condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2023, the Company had approximately $ 32,000 26.3 The Company has no revenues and has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss and net cash used in operating activities of $ 4,150,375 655,155 26.3 60.0 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, the war in Ukraine, the war in Israel, federal bank failures or other world-wide events, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, it will cease operations. . The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) Reverse Stock Split On September 30, 2022, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of 1-for-20 1-for-20 reverse stock split All disclosures of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of September 30, 2023, the Company had approximately $ 32,000 The Company deposits its cash with a major financial institution that may at times exceed the federally insured limit. As of September 30, 2023, the Company’s cash balance did not exceed the federal deposit insurance limit. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad levels. The following is a brief description of those six levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of September 30, 2023, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 4.3 4.13 5.55 263 408 0 1.10 SCHEDULE OF FAIR VALUE MEASUREMENTS Fair Value Measurements at September 30, 2023 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 6,892,612 $ 6,892,612 Total $ - $ - $ 6,892,612 $ 6,892,612 A roll forward of the level 3 valuation financial instruments is as follows: SCHEDULE OF ROLL FORWARD OF LEVEL 3 FINANCIAL INSTRUMENTS Nine Months Ended September 30, 2023 Warrants Notes Total Balance at December 31, 2022 $ 5,074,915 $ 1,311,369 $ 6,386,284 Initial valuation of derivative liabilities included in debt discount 406,846 - 406,846 Initial valuation of derivative liabilities included in derivative expense 564,483 - 564,483 Reclassification of derivative liabilities to gain on debt extinguishment - (115,512 ) (115,512 ) Change in fair value included in derivative expense (income) (1,337,166 ) 987,677 (349,489 ) Balance at September 30, 2023 $ 4,709,078 $ 2,183,534 $ 6,892,612 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid-in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the warrant is treated as a derivative liability, the derivative liability is recorded at fair value and the difference between the derivative liability and debt discount is recorded as an initial derivative expense. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Recently Issued Accounting Pronouncements Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following number of shares for the nine-month periods ended September 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 111,743,222 2,389,770 Warrants 161,984,924 5,192,652 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 191,335 178,833 Total 273,925,315 7,786,089 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. Reclassifications Certain reclassifications have been made in the consolidated financial statements to conform to the current period presentation. Such reclassifications had no impact on the Company’ previously reported consolidated financial position or results of operations. Specifically, on the consolidated financial statements, all amounts are now reflected in whole dollars and all rounding to thousands has been eliminated. Additionally, on the consolidated statements of operations, professional fees and compensation expense has been reclassified from general and administrative expenses and are shown separately as part of operating expenses. Furthermore, for the nine months ended September 30, 2022, certain reclassifications were made on the consolidated statement of cash flows to conform to the current presentation. The reclassification on the 2022 consolidated statement of cash flow increased cash flows used in operations by approximately $ 94,000 94,000 |
PREPAID EXPENSES
PREPAID EXPENSES | 9 Months Ended |
Sep. 30, 2023 | |
Prepaid Expenses | |
PREPAID EXPENSES | NOTE 3 – PREPAID EXPENSES As of September 30, 2023, and December 31, 2022, prepaid expenses totaled $ 11,686 46,750 |
NOTES PAYABLE AND CONVERTIBLE P
NOTES PAYABLE AND CONVERTIBLE PROMISSORY NOTES | 9 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
NOTES PAYABLE AND CONVERTIBLE PROMISSORY NOTES | NOTE 4 – NOTES PAYABLE AND CONVERTIBLE PROMISSORY NOTES The following table summarizes the Company’s outstanding term loans: SCHEDULE OF OUTSTANDING TERM LOANS September 30, December 31, 2019 Term Loan $ 5,676,900 $ 5,676,900 2022 Term Loans 3,045,634 2,365,079 2023 Term Loans 1,332,143 - Notes payable 10,054,677 8,041,979 Unamortized discounts and fees (394,322 ) (709,001 ) Loans payable $ 9,660,355 $ 7,332,978 As of September 30, 2023, the 2019 Term Loan was in default. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) 2019 Term Loan During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes in the aggregate principal amount of approximately $ 5.7 707,000 The promissory notes accrued interest at a rate of 12 15 The unpaid principal balance of the notes, plus accrued and unpaid interest thereon, matured on June 28, 2020 On June 26, 2021, the holders of the 2019 Term Loans agreed to subordinate their lien and security interest in the assets of the Company and its subsidiaries as set forth in the Security Agreement dated June 28, 2019, to the holders of the June 2021 convertible notes. On April 19, 2022, a majority of the noteholders of the secured non-convertible promissory notes of the Company issued between June 18, 2019, and August 5, 2019, which matured on August 5, 2020, consented to forbear collection efforts until September 30, 2022. Accordingly, the collateral agent for the noteholders in consideration of the signed noteholder agreements agreed to forbear all notes outstanding. On November 16, 2022, holders of outstanding promissory notes representing a majority of the outstanding principal and accrued interest of the Notes, agreed to amend the Notes to make them automatically convertible into units consisting of a new series of convertible preferred stock and warrants upon an up listing financing transaction in which the Company’s common stock is listed on The Nasdaq Capital Market or the NYSE American, in exchange for the Holders agreeing to forbear repayment of their Notes and accrued interest until the Up listing Transaction has been completed. The terms for the amendment of the Notes include no less than the following: ● The Notes will automatically convert upon the Uplisting Transaction into the Preferred Stock at 90 ● In addition, each Holder will receive 0.3 1.00 ● The shares of Preferred Stock will be subject to a six-month lock-up period from date of issuance; and ● The Company has agreed to register the Holders’ sale of the shares of common stock issuable upon conversion of the Preferred Stock and upon the exercise of the Warrants such that those shares will be freely tradeable following the up-list transaction and expiration of the lock-up period. The shares of the Preferred Stock will be entitled to vote on an as-converted-to-common basis together with the Company’s common stock. The shares of the Preferred Stock will automatically convert into shares of common stock upon expiration of the lock-up period at the conversion price of a percentage of a 30-day VWAP of common stock. The interest on the Notes, as accrued through the date of conversion, will convert into common stock at the offering price for the up-list transaction. The Company recognized $ 214,633 636,902 As of September 30, 2023, the Company had $ 3,515,399 5,676,900 3,515,399 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) 2022 Term Loan – May On May 11, 2022, the Company entered into a Securities Purchase Agreement with investors whereby the Company issued the Purchasers Original Issue Discount Promissory Notes in the aggregate principal amount of $ 2,222,222 222,222 2,000,000 1,111,112 19,231 1,692,200 307,800 The Notes were due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. The Company recorded a total debt discount of $ 1,693,000 222,222 307,800 11,820 1,151,137 The Company’s obligations under the Notes are secured by a first priority lien on all of the assets of the Company and its wholly-owned subsidiaries pursuant to a Security Agreement, dated May 11, 2022 and among the Company, its wholly-owned subsidiaries, the Purchasers, and the lead investor as the collateral agent. The Warrants were exercisable for a 66 November 11, 2027 0.80 On January 10, 2023, the exercise price of the warrants was adjusted to $ 0.56 On April 14, 2023, the exercise price of the warrants was adjusted to $ 0.279 On April 28, 2023, the exercise price of the warrants was adjusted to $ 0.18 On May 10, 2023, the exercise price of the warrants was adjusted to $ 0.054 On May 11, 2023, the Company elected to extend the maturity date on the loan by six-months to November 11, 2023 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) On June 23, 2023, the exercise price of the warrants was adjusted to $ 0.036 During the three months ended September 30, 2023, the exercise price of the warrants was adjusted from $ 0.036 0.00845 During the three and nine months ended September 30, 2023, the Company increased the outstanding principal amount of the notes by approximately $ 0 680,600 For the three and nine months ended September 30, 2023, the Company recognized approximately $ 0 602,979 57,272 163,602 562,300 663,300 45,400 70,600 As of September 30, 2023, the Company has recorded $ 2,902,777 279,651 2022 Term Loan – December On December 14, 2022, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which the Company issued and sold the investor a non-convertible Original Issue Discount Senior Secured Promissory Note in the principal amount of $ 142,857 158,537 100,000 82,400 17,600 42,857 The Notes are due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or December 14, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. The unpaid principal amount of this Note, together with any interest accrued but unpaid thereon, may, at the sole discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company on the closing date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”). The Company recorded a total debt discount of $ 111,523 42,857 17,600 51,066 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) The Company’s obligations under the Notes are secured by a first priority lien on all of the assets of the Company and its wholly-owned subsidiaries pursuant to a Security Agreement, dated May 11, 2022 and among the Company, its wholly-owned subsidiaries, the Purchasers, and the lead investor as the collateral agent. The Warrants were exercisable for a 66 June 15, 2028 0.82 On January 10, 2023, the exercise price of the warrants was adjusted to $ 0.56 On April 14, 2023, the exercise price of the warrants was adjusted to $ 0.279 On April 28, 2023, the exercise price of the warrants was adjusted to $ 0.18 On May 10, 2023, the exercise price of the warrants was adjusted to $ 0.054 On June 23, 2023, the exercise price of the warrants was adjusted to $ 0.036 During the three months ended September 30, 2023, the exercise price of the warrants was adjusted from $ 0.036 0.00845 For the three and nine months ended September 30, 2023, the Company recognized approximately $ 28,109 83,413 2,921 8,627 No As of September 30, 2023, the Company has recorded $ 142,857 9,191 22,610 2023 Term Loans January 18, 2023 On January 18, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors pursuant to which the Company issued and sold the investors a non-convertible Original Issue 30 285,714 452,962 200,000 173,850 26,150 The Company also agreed to increase the principal amount of prior Original Issue Discount Promissory Notes issued to the investor in May 2022 by 25 277,777 277,777 The Notes are due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or January 18, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) The unpaid principal amount of this Note, together with any interest accrued but unpaid thereon, may, at the sole discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company on the closing date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”). The Company recorded a total debt discount of $ 203,000 85,700 26,200 91,100 The Warrants were exercisable for a 66 July 18, 2028 0.82 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 During the three months ended September 30, 2023, the exercise price of the warrants was adjusted from $ 0.036 0.00845 During both the three and nine months ended September 30, 2023, the Company increased the outstanding principal amount of the notes by $ 64,286 For the three and nine months ended September 30, 2023, the Company recognized approximately $ 51,170 142,386 7,219 18,609 No As of September 30, 2023, the Company has recorded $ 350,000 18,609 60,625 February 3, 2023 On February 3, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which the Company issued and sold the investor a non-convertible Original Issue 30 267,857 424,652 150,000 133,850 16,150 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) The Notes are due on the earliest to occur of (i) the 12-month anniversary of the original issuance date of the Notes, or February 3, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. The unpaid principal amount of this Note, together with any interest accrued but unpaid thereon, may, at the sole discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company on the closing date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”) The Company recorded a total debt discount of approximately $ 224,000 64,286 53,571 16,100 90,049 The Warrants were exercisable for a 66 August 3, 2028 0.82 On April 14, 2023, the exercise price of the warrants was adjusted to $ 0.279 On April 28, 2023, the exercise price of the warrants was adjusted to $ 0.18 On May 10, 2023, the exercise price of the warrants was adjusted to $ 0.054 On June 23, 2023, the exercise price of the warrants was adjusted to $ 0.036 During the three months ended September 30, 2023, the exercise price of the warrants was adjusted from $ 0.036 0.00845 For the three and nine months ended September 30, 2023, the Company recognized $ 56,462 147,292 5,536 14,405 No As of September 30, 2023, the Company has recorded $ 267,857 14,405 76,714 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) February 16, 2023 On February 16, 2023, the Company entered into a Securities Purchase Agreements with two accredited investors pursuant to which the Company issued and sold the investor a non-convertible Original Issue 30 214,286 339,722 150,000 133,850 16,150 The Company also agreed to increase the principal amount of prior Original Issue Discount Promissory Notes issued to the investors in May 2022 by 25 69,444 69,444 The Notes are due on the earlier of (i) the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12-month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any). The Notes may, at the discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company (the “Convertible Preferred Stock”) on the closing date of the Qualified Financing. In the event of the conversion, the holder will receive a number of shares of Convertible Preferred Stock equal to the quotient obtained by dividing (i) the unpaid principal amount of this Note (together with any interest accrued but unpaid thereon) by (ii) the closing price of the securities issued in the Qualified Financing on the closing date of the Qualified Financing. Upon issuance, the conversion price of the Convertible Preferred Stock will be equal to the closing price of the securities issued in the Qualified Financing, subject to adjustment. The Company recorded a total debt discount of $ 163,646 64,286 16,150 83,210 The Warrants were exercisable for a 66 August 16, 2028 0.82 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 During the three months ended September 30, 2023, the exercise price of the warrants was adjusted from $ 0.036 0.00845 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) During the three and nine months ended September 30, 2023, the Company increased the outstanding principal amount of the notes by $ 0 69,444 For the three and nine months ended September 30, 2023, the Company recognized $ 41,248 101,775 5,757 13,147 No As of September 30, 2023, the Company has recorded $ 278,571 13,147 61,872 April 28, 2023 On April 28, 2023, the Company entered into Securities Purchase Agreements with three accredited investors pursuant to which the Company issued and sold the investors non-convertible Original Issue 30 285,714 452,964 200,000 The Company also agreed to increase the principal amount of prior Original Issue Discount Promissory Notes issued to the investor in May 2022 and January 2023 by 30 461,904 The Notes are due on the earlier of (i) the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12-month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any). The Notes may, at the discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company (the “Convertible Preferred Stock”) on the closing date of the Qualified Financing. In the event of the conversion, the holder will receive a number of shares of Convertible Preferred Stock equal to the quotient obtained by dividing (i) the unpaid principal amount of this Note (together with any interest accrued but unpaid thereon) by (ii) the closing price of the securities issued in the Qualified Financing on the closing date of the Qualified Financing. Upon issuance, the conversion price of the Convertible Preferred Stock will be equal to the closing price of the securities issued in the Qualified Financing, subject to adjustment. The Company recorded a total debt discount of $ 166,364 85,714 80,650 The Warrants issued with promissory notes were exercisable for a 66 0.82 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 During the three months ended September 30, 2023, the exercise price of the warrants was adjusted from $ 0.036 0.00845 For the three and nine months ended September 30, 2023, the Company recognized $ 41,933 71,104 5,905 9,968 No As of September 30, 2023, the Company has recorded $ 285,714 9,968 95,261 June 22, 2023 On June 22, 2023, the Company entered into Securities Purchase Agreements with four accredited investors pursuant to which the Company issued and sold the investors non-convertible Original Issue Discount Senior Secured Promissory Notes in the aggregate principal amount of $ 150,000 3,000,000 105,000 The Notes are due on the earlier of (i) the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12-month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any). The Notes may, at the discretion of the Company, be converted into shares of a new class of convertible preferred stock of the Company (the “Convertible Preferred Stock”) on the closing date of the Qualified Financing. In the event of the conversion, the holder will receive a number of shares of Convertible Preferred Stock equal to the quotient obtained by dividing (i) the unpaid principal amount of this Note (together with any interest accrued but unpaid thereon) by (ii) the closing price of the securities issued in the Qualified Financing on the closing date of the Qualified Financing. Upon issuance, the conversion price of the Convertible Preferred Stock (the “Preferred Conversion Price”) will be equal to the closing price of the securities issued in the Qualified Financing, subject to adjustment. The Notes provide for certain customary events of default which include failure to maintain the required reserve of shares for the Warrants, a restatement of the financial statements of the Company resulting in a reduction to the stock price by an enumerated threshold, and certain other customary events of default, subject to certain exceptions and limitations. Upon an event of default, the Notes will become immediately due and payable at a 125 100 The Notes contain customary restrictive covenants which apply for as long as at least 75% of the Notes remain outstanding, including covenants against incurring new indebtedness or liens, repurchasing shares of common stock or common stock equivalents, paying dividends or distributions on equity securities, and transactions with affiliates, subject to certain exceptions and limitations. In addition, the SPA imposes certain additional negative covenants and obligations on the Company, including a prohibition on filing a registration statement (other than on Form S-8) unless at least 30% of the Notes have been repaid as of such filing, a prohibition on incurring new indebtedness at any time while any Notes are outstanding, and a 90-day restriction against issuing shares of common stock or common stock equivalents, subject to certain exceptions and limitations. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) The Company recorded a total debt discount of $ 106,790 45,000 61,790 The Warrants issued with promissory notes were exercisable for a 66 0.05 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 During the three months ended September 30, 2023, the exercise price of the warrants was adjusted from $ 0.036 0.00845 For the three and nine months ended September 30, 2023, the Company recognized $ 26,917 29,550 3,100 3,400 No As of September 30, 2023, the Company has recorded $ 150,000 3,400 77,240 CONVERTIBLE PROMISSORY NOTES The following table summarizes the Company’s outstanding convertible notes as of September 30, 2023, and December 31, 2022: SCHEDULE OF CONVERTIBLE PROMISSORY NOTES September 30, 2023 December 31, 2022 Convertible Notes $ 1,168,765 $ 1,319,024 Unamortized discounts - (67,328 ) Convertible notes payable, net $ 1,168,765 $ 1,251,696 All convertible notes including accrued interest were in default as of the issuance date of this Report. As of September 30, 2023, accrued interest totaled $ 589,458 Secured Convertible Promissory Note – February 2020 On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes with a principal of $ 550,500 10 499,950 The Convertible Notes matured on August 5, 2020 10 18 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) Until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $ 10.00 70 60 1.00 The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the Warrants of approximately $ 322,000 30,000 53,000 21,000 38,000 381,000 On January 27, 2022, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.78 On January 10, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.56 On April 14, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.279 On April 28, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.18 On May 10, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.054 On June 23, 2023, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.036 During the three months ended September 30, 2023, the conversion price of the notes and exercise price of the warrants was adjusted from $ 0.036 0.00845 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) The Company recognized $ 21,038 62,429 21,038 66,846 As of September 30, 2023, the Company remains in default on the repayment of $ 457,359 251,493 140 The 40% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10 58,055 52,500 5,555 December 26, 2020 10 14,000 18 The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.40 65 50,000 203,000 The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 On January 27, 2022, the conversion price of the note was adjusted to the lower of 65 0.78 On January 10, 2023, the conversion price of the note was adjusted to the lower of 65 0.56 On April 14, 2023, the conversion price of the note was adjusted to the lower of 65 0.279 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) On April 28, 2023, the conversion price of the note was adjusted to the lower of 65 0.18 On May 10, 2023, the conversion price of the note was adjusted to the lower of 65 0.054 On June 23, 2023, the conversion price of the note was adjusted to the lower of 65 0.036 During the three months ended September 30, 2023, the conversion price of the note was adjusted to the lower of 65 0.00845 For the three months ended September 30, 2023 and 2022, the Company recognized $ 2,641 2,670 7,925 7,925 As of September 30, 2023, the Company remains in default on the repayment of principal of $ 58,055 34,104 140 The 40% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10 111,111 100,000 1.40 70 1.00 The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. The Company recorded approximately $ 9,000 The interest rate on the note was 10 18 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) Additionally, the Company issued the noteholder 79,366 1.60 1.00 47,619 57,000 0.16 262.27 0.92 The Company recorded a discount related to the warrants of approximately $ 66,000 6,000 5,000 45,000 69,000 5,000 4,000 On January 27, 2022, the exercise price of the notes and warr |
LICENSING AGREEMENTS
LICENSING AGREEMENTS | 9 Months Ended |
Sep. 30, 2023 | |
Licensing Agreements | |
LICENSING AGREEMENTS | NOTE 5 - LICENSING AGREEMENTS Les Laboratories Servier As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions). On January 4, 2021, the licensor terminated the licensing agreement with the Company for the commercialization of Prestalia®. As of September 30, 2023 and December 31, 2022, the Company had $ 24,500 No License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000 |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Sep. 30, 2023 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 6 - RELATED PARTY TRANSACTIONS Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. An unpaid balance for previous years services performed under the agreement of $ 4,392 In addition, as of September 30, 2023 and December 31, 2022 the Company owed various officers and directors $ 57,500 21,176 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) |
STOCKHOLDERS_ EQUITY
STOCKHOLDERS’ EQUITY | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
STOCKHOLDERS’ EQUITY | NOTE 7 - STOCKHOLDERS’ EQUITY Preferred Stock Adhera has authorized 100,000 1,000 90,000 1,200 220 3,500 2,200 6,000 Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 5,100 voting rights of 33.33 votes 150.00 As of September 30, 2023, 100 Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 300 voting rights of 62.5 votes 80.00 5 As of September 30, 2023, 40 Series E Convertible Preferred Stock and Warrants The Series E Preferred Stock has a stated value of $ 5,000 8 10.00 February 10, 2020 On March 19, 2021, the exercise price of the Series E warrants was adjusted from $ 10.00 1.00 25,900 25,900 On January 27, 2022, the exercise price of the Series E warrants was adjusted to $ 0.78 0.78 On May 17, 2022, the Company effected the conversion of 3,059 5.1 2,035,306 10.00 On January 10, 2023, the exercise price of the Series E warrants was adjusted to $ 0.56 0.56 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On May 17, 2023, a total of 1,453,028 The Company had accrued dividends on the Series E Preferred stock of $ 578,333 At September 30, 2023, there were 267 Series F Convertible Preferred Shares and Warrants The Series F Preferred Stock has a stated value of $ 5,000 8 10.00 February 10, 2020 On March 19, 2021, the exercise price of the Series F warrants was adjusted from $ 10.00 to $ 1.00 upon the conversion of $ 25,900 of debt for 25,900 shares of common stock. On January 27, 2022, the exercise price of the Series F warrants was adjusted to $ 0.78 0.78 On May 17, 2022, the Company effected the conversion of 358 543,000 233,127 10.00 On January 10, 2023, the exercise price of the Series F warrants was adjusted to $ 0.56 0.56 On April 14, 2023, the conversion price of the warrants was adjusted to $ 0.279 On April 28, 2023, the conversion price of the warrants was adjusted to $ 0.18 On May 10, 2023, the conversion price of the warrants was adjusted to $ 0.054 On June 23, 2023, the conversion price of the warrants was adjusted to $ 0.036 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) During the three months ended September 30, 2023, the conversion price of the warrants was adjusted to $ 0.00845 As of September 30, 2023, the Company had a total of 154,425 At September 30, 2023, and December 31, 2022, there were no Series G Convertible Preferred Shares The Series G Preferred Stock has a stated value of $ 5,000 8 10.00 As of September 30, 2023, and December 31, 2022, no Common Stock On January 27, 2022, the Company issued 12,721 9,500 422 28,000 18,000 23,000 23,000 5,000 On March 15, 2022, the Company issued 2,500 3,596 On March 15, 2022, the Company issued 10,000 14,384 On May 11, 2022, the Company issued 19,231 11,820 On May 17, 2022, the Company effected the conversion of 3,059 5.1 2,035,306 10.00 On May 17, 2022, the Company effected the conversion of 358 541,000 233,127 10.00 On January 10, 2023, the Company issued 17,861 3,839 6,161 0.56 5,000 On April 14, 2023, the holder of the March 15, 2022, convertible note converted $ 10,000 0.28 35,716 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) On April 28, 2023, the holder of the March 15, 2022, convertible note converted $ 21,314 6,586 0.18 155,000 On May 10, 2023, the holder of the March 15, 2022, convertible note converted $ 6,001 489 0.054 120,000 On May 30, 2023, the holder of the March 15, 2022, convertible note converted $ 9,203 756 0.059 170,000 On June 23, 2023, the holder of the March 15, 2022, convertible note converted $ 5,697 799 0.039 180,000 During the three months ended September 30, 2023, the Company issued 819,458 6,900 2,568 Secured Convertible Promissory Note – June 2021. On September 1, 2023 the holder of the March 15, 2022, convertible note converted $ 324 2,133 0.0117 210,000 During the nine months ended September 30, 2023, the Company recorded the difference between the converted amount and the fair value of the common stock issued as a loss from extinguishment of debt which amounted to $ 22,591 110,512 87,921 22,591 110,512 87,921 On September 8, 2023, an investor exercised 750,000 300,000 Treasury Stock On May 12, 2022, the Company repurchased 5,954 2,000 Warrants As of September 30, 2023, there were 161,984,924 0.015 SCHEDULE OF STOCKHOLDER’ EQUITY NOTE, WARRANTS OR RIGHTS Warrants issued with: Shares 2023 2024 2025 2026 2027 and Series F Preferred Stock 154,425 154,425 - - - - Bridge Loans 5,939,950 - - - - 5,939,950 Convertible Notes (CVN) 155,873,108 - 9,041,703 115,679,985 31,151,420 - Other 17,441 504 16,937 - - - Total Warrants 161,984,924 154,929 9,058,640 115,679,985 31,151,420 5,939,950 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) The above table includes 155,825,488 SCHEDULE OF WARRANTS of Warrants Warrants as of December 31, 2022 6,785,914 Issued as a result of price adjustments on convertible notes 55,317,596 Variable quantity of warrants related to the February 2020 note 97,481,393 Warrants issued with 2023 Bridge Notes 4,670,301 Warrant cashless exercise (750,000 ) Expirations (1,520,280 ) Warrants as of September 30, 2023 161,984,924 The intrinsic value of outstanding warrants as of September 30, 2023, was approximately $ 3.4 As discussed in Note 2 above, the Company has issued convertible notes and warrants with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock and various default provisions related to the payment of the notes in Company stock. The number of shares of common stock to be issued under the convertible notes and warrants is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the convertible notes is therefore, indeterminate. Due to the fact that the number of shares of common stock are indeterminable, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative as of that date. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the warrants were recorded as derivative liabilities. On September 30, 2023, the Company evaluated all outstanding warrants to determine whether these instruments are tainted and, due to reasons discussed above, all warrants outstanding were considered tainted and were therefore, accounted for as derivative liabilities. Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain warrants to reduce certain conversion prices during the six-month period to $ 0.036 |
STOCK INCENTIVE PLANS
STOCK INCENTIVE PLANS | 9 Months Ended |
Sep. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
STOCK INCENTIVE PLANS | NOTE 8 - STOCK INCENTIVE PLANS Stock Options The following table summarizes stock option activity for the nine months ended September 30, 2023: SCHEDULE OF SHARE BASED PAYMENTS ARRANGEMENT, OPTION ACTIVITY Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2022 19,000 $ 19.60 Options expired / forfeited (19,000 ) $ 19.60 Outstanding, September 30, 2023 - $ - Exercisable, September 30, 2023 - $ - No ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 9 - COMMITMENTS AND CONTINGENCIES Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs. Licensing Agreement – MLR 1019 On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC (“Melior II”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use Melior II’s Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 5 The license agreement terminates upon the last expiration of the patents licensed by the Company, which is presently 2038 subject to any potential extensions and renewals of any of such patents. If the Company fails to have its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using Melior II’s data shall terminate. Additionally, if the Company has completed the necessary steps to effect an Uplisting Event, the Company will have the option to purchase all rights held by Melior II on the MLR-1019 licensed products in consideration for 10 2.5 As of September 30, 2023, no performance milestones requiring cash consideration had been met under the agreement. Licensing Agreement – MLR 1023 On August 20, 2021, we as licensee entered into the exclusive license agreement with Melior Pharmaceuticals I, Inc. (“MP1”) regarding the development and commercialization of MPI’s MLR-1023 (the “MLR-1023 Agreement”) We refer to MelliorII and MPI as “MP” or “Melior”. This second license is for the development and commercialization of MLR-1023, which is being developed as a novel therapeutic for Type 1 diabetes. Under the original terms of the MLR-1023 Agreement, if the Company failed to raise $4.0 million within 120 days of the effective date of the agreement then the MLR-1023 Agreement would immediately terminate unless, by 120 days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 days would be provided to allow for the completion of the raise (the “Raise Requirement”). On October 20, 2021, we as licensee expanded the exclusive licensing agreement with Melior I to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) On February 16, 2022, an addendum to the MLR-1023 Agreement dated August 4, 2021 (the “First Addendum”), was executed by the Company and Melior, which extended the Raise Requirement to June 16, 2022. On July 20, 2022, the Company and Melior entered into the Second Addendum to the License Agreement (the “Second Addendum”). In accordance with the Second Addendum and subject to the terms and conditions therein, the Raise Requirement was extended to February 1, 2023, in exchange for a $ 136,921 500,000 On February 16, 2022, an addendum to the MLR-1023 Agreement dated August 4, 2021 (the “First Addendum”), was executed by the Company and Melior, which extended the requirement by the Company to raise $4 million (the “Raise Requirement”) to June 16, 2022. On July 18, 2022, the Company and Melior entered into the Second Addendum to the License Agreement (the “Second Addendum”). In accordance with the Second Addendum and subject to the terms and conditions therein, the Raise Requirement was extended to February 1, 2023, in exchange for a $ 136,921 500,000 As of February 1, 2023, the Company had not raised the additional $ 500,000 On August 11, 2023, the Company and Biodexa Pharmaceuticals PLC (“Biodexa”) entered into a non-binding summary of proposals for the assignment of the MLR-1023 Agreement to Biodexa. In connection with the summary of proposals, in August 2023, the Company received a $ 100,000 As of September 30, 2023, no performance milestones requiring cash consideration had been met under the agreement. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2023 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 10 - SUBSEQUENT EVENTS Conversion of Principal on Convertible Note From October 1, 2023 to November 17, 2023, certain convertible noteholders converted $ 20,749 3,654 1,751,988 On October 2, 2023, the Company issued 300,000 750,000 |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the nine months ended September 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period. |
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries and eliminates any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. |
Going Concern and Management’s Liquidity Plans | Going Concern and Management’s Liquidity Plans The accompanying unaudited condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2023, the Company had approximately $ 32,000 26.3 The Company has no revenues and has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss and net cash used in operating activities of $ 4,150,375 655,155 26.3 60.0 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, the war in Ukraine, the war in Israel, federal bank failures or other world-wide events, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, it will cease operations. . The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) |
Reverse Stock Split | Reverse Stock Split On September 30, 2022, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State to effect a reverse stock split of all outstanding shares of the Company’s common stock at a ratio of 1-for-20 1-for-20 reverse stock split All disclosures of common shares and per common share data in the accompanying consolidated financial statements and related notes reflect the reverse stock split for all periods presented. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. As of September 30, 2023, the Company had approximately $ 32,000 The Company deposits its cash with a major financial institution that may at times exceed the federally insured limit. As of September 30, 2023, the Company’s cash balance did not exceed the federal deposit insurance limit. |
Use of Estimates | Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad levels. The following is a brief description of those six levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of September 30, 2023, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 4.3 4.13 5.55 263 408 0 1.10 SCHEDULE OF FAIR VALUE MEASUREMENTS Fair Value Measurements at September 30, 2023 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 6,892,612 $ 6,892,612 Total $ - $ - $ 6,892,612 $ 6,892,612 A roll forward of the level 3 valuation financial instruments is as follows: SCHEDULE OF ROLL FORWARD OF LEVEL 3 FINANCIAL INSTRUMENTS Nine Months Ended September 30, 2023 Warrants Notes Total Balance at December 31, 2022 $ 5,074,915 $ 1,311,369 $ 6,386,284 Initial valuation of derivative liabilities included in debt discount 406,846 - 406,846 Initial valuation of derivative liabilities included in derivative expense 564,483 - 564,483 Reclassification of derivative liabilities to gain on debt extinguishment - (115,512 ) (115,512 ) Change in fair value included in derivative expense (income) (1,337,166 ) 987,677 (349,489 ) Balance at September 30, 2023 $ 4,709,078 $ 2,183,534 $ 6,892,612 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) |
Convertible Debt and Warrant Accounting | Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid-in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the warrant is treated as a derivative liability, the derivative liability is recorded at fair value and the difference between the derivative liability and debt discount is recorded as an initial derivative expense. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. |
Net Loss per Common Share | Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following number of shares for the nine-month periods ended September 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 111,743,222 2,389,770 Warrants 161,984,924 5,192,652 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 191,335 178,833 Total 273,925,315 7,786,089 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited) |
Stock-Based Compensation | Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. |
Income Taxes | Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. |
Reclassifications | Reclassifications Certain reclassifications have been made in the consolidated financial statements to conform to the current period presentation. Such reclassifications had no impact on the Company’ previously reported consolidated financial position or results of operations. Specifically, on the consolidated financial statements, all amounts are now reflected in whole dollars and all rounding to thousands has been eliminated. Additionally, on the consolidated statements of operations, professional fees and compensation expense has been reclassified from general and administrative expenses and are shown separately as part of operating expenses. Furthermore, for the nine months ended September 30, 2022, certain reclassifications were made on the consolidated statement of cash flows to conform to the current presentation. The reclassification on the 2022 consolidated statement of cash flow increased cash flows used in operations by approximately $ 94,000 94,000 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
SCHEDULE OF FAIR VALUE MEASUREMENTS | SCHEDULE OF FAIR VALUE MEASUREMENTS Fair Value Measurements at September 30, 2023 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 6,892,612 $ 6,892,612 Total $ - $ - $ 6,892,612 $ 6,892,612 |
SCHEDULE OF ROLL FORWARD OF LEVEL 3 FINANCIAL INSTRUMENTS | A roll forward of the level 3 valuation financial instruments is as follows: SCHEDULE OF ROLL FORWARD OF LEVEL 3 FINANCIAL INSTRUMENTS Nine Months Ended September 30, 2023 Warrants Notes Total Balance at December 31, 2022 $ 5,074,915 $ 1,311,369 $ 6,386,284 Initial valuation of derivative liabilities included in debt discount 406,846 - 406,846 Initial valuation of derivative liabilities included in derivative expense 564,483 - 564,483 Reclassification of derivative liabilities to gain on debt extinguishment - (115,512 ) (115,512 ) Change in fair value included in derivative expense (income) (1,337,166 ) 987,677 (349,489 ) Balance at September 30, 2023 $ 4,709,078 $ 2,183,534 $ 6,892,612 |
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE | The following number of shares for the nine-month periods ended September 30, 2023 and 2022, have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2023 2022 Stock options outstanding - 19,000 Convertible notes 111,743,222 2,389,770 Warrants 161,984,924 5,192,652 Series C Preferred Stock 3,334 3,334 Series D Preferred Stock 2,500 2,500 Series E Preferred Stock 191,335 178,833 Total 273,925,315 7,786,089 |
NOTES PAYABLE AND CONVERTIBLE_2
NOTES PAYABLE AND CONVERTIBLE PROMISSORY NOTES (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
SCHEDULE OF OUTSTANDING TERM LOANS | The following table summarizes the Company’s outstanding term loans: SCHEDULE OF OUTSTANDING TERM LOANS September 30, December 31, 2019 Term Loan $ 5,676,900 $ 5,676,900 2022 Term Loans 3,045,634 2,365,079 2023 Term Loans 1,332,143 - Notes payable 10,054,677 8,041,979 Unamortized discounts and fees (394,322 ) (709,001 ) Loans payable $ 9,660,355 $ 7,332,978 |
SCHEDULE OF CONVERTIBLE PROMISSORY NOTES | The following table summarizes the Company’s outstanding convertible notes as of September 30, 2023, and December 31, 2022: SCHEDULE OF CONVERTIBLE PROMISSORY NOTES September 30, 2023 December 31, 2022 Convertible Notes $ 1,168,765 $ 1,319,024 Unamortized discounts - (67,328 ) Convertible notes payable, net $ 1,168,765 $ 1,251,696 |
SCHEDULE OF FAIR VALUE OF DERIVATIVE LIABILITIES ESTIMATED ISSUANCE AND VALUATION MODE | During the nine months ended September 30, 2023, the fair value of the derivative liabilities was estimated at issuance and at the September 30, 2023, using the Binomial Lattice valuation model with the following assumptions: SCHEDULE OF FAIR VALUE OF DERIVATIVE LIABILITIES ESTIMATED ISSUANCE AND VALUATION MODE Dividend rate — % Term (in years) 0.00 1.10 Volatility 178.2 409 % Risk-free interest rate 3.36 5.55 % |
STOCKHOLDERS_ EQUITY (Tables)
STOCKHOLDERS’ EQUITY (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
SCHEDULE OF STOCKHOLDER’ EQUITY NOTE, WARRANTS OR RIGHTS | SCHEDULE OF STOCKHOLDER’ EQUITY NOTE, WARRANTS OR RIGHTS Warrants issued with: Shares 2023 2024 2025 2026 2027 and Series F Preferred Stock 154,425 154,425 - - - - Bridge Loans 5,939,950 - - - - 5,939,950 Convertible Notes (CVN) 155,873,108 - 9,041,703 115,679,985 31,151,420 - Other 17,441 504 16,937 - - - Total Warrants 161,984,924 154,929 9,058,640 115,679,985 31,151,420 5,939,950 |
SCHEDULE OF WARRANTS | SCHEDULE OF WARRANTS of Warrants Warrants as of December 31, 2022 6,785,914 Issued as a result of price adjustments on convertible notes 55,317,596 Variable quantity of warrants related to the February 2020 note 97,481,393 Warrants issued with 2023 Bridge Notes 4,670,301 Warrant cashless exercise (750,000 ) Expirations (1,520,280 ) Warrants as of September 30, 2023 161,984,924 |
STOCK INCENTIVE PLANS (Tables)
STOCK INCENTIVE PLANS (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
SCHEDULE OF SHARE BASED PAYMENTS ARRANGEMENT, OPTION ACTIVITY | The following table summarizes stock option activity for the nine months ended September 30, 2023: SCHEDULE OF SHARE BASED PAYMENTS ARRANGEMENT, OPTION ACTIVITY Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2022 19,000 $ 19.60 Options expired / forfeited (19,000 ) $ 19.60 Outstanding, September 30, 2023 - $ - Exercisable, September 30, 2023 - $ - |
SCHEDULE OF FAIR VALUE MEASUREM
SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Platform Operator, Crypto-Asset [Line Items] | ||
Derivative liability | $ 6,892,612 | $ 6,386,284 |
Total | 6,892,612 | |
Fair Value, Inputs, Level 1 [Member] | ||
Platform Operator, Crypto-Asset [Line Items] | ||
Derivative liability | ||
Total | ||
Fair Value, Inputs, Level 2 [Member] | ||
Platform Operator, Crypto-Asset [Line Items] | ||
Derivative liability | ||
Total | ||
Fair Value, Inputs, Level 3 [Member] | ||
Platform Operator, Crypto-Asset [Line Items] | ||
Derivative liability | 6,892,612 | |
Total | $ 6,892,612 |
SCHEDULE OF ROLL FORWARD OF LEV
SCHEDULE OF ROLL FORWARD OF LEVEL 3 FINANCIAL INSTRUMENTS (Details) | 9 Months Ended |
Sep. 30, 2023 USD ($) | |
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] | |
Balance at December 31, 2022 | $ 6,386,284 |
Initial valuation of derivative liabilities included in debt discount | 406,846 |
Initial valuation of derivative liabilities included in derivative expense | 564,483 |
Reclassification of derivative liabilities to gain on debt extinguishment | (115,512) |
Change in fair value included in derivative expense (income) | (349,489) |
Balance at September 30, 2023 | 6,892,612 |
Convertible Notes [Member] | |
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] | |
Balance at December 31, 2022 | 1,311,369 |
Initial valuation of derivative liabilities included in debt discount | |
Initial valuation of derivative liabilities included in derivative expense | |
Reclassification of derivative liabilities to gain on debt extinguishment | (115,512) |
Change in fair value included in derivative expense (income) | 987,677 |
Balance at September 30, 2023 | 2,183,534 |
Warrant [Member] | |
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] | |
Balance at December 31, 2022 | 5,074,915 |
Initial valuation of derivative liabilities included in debt discount | 406,846 |
Initial valuation of derivative liabilities included in derivative expense | 564,483 |
Reclassification of derivative liabilities to gain on debt extinguishment | |
Change in fair value included in derivative expense (income) | (1,337,166) |
Balance at September 30, 2023 | $ 4,709,078 |
SCHEDULE OF ANTI-DILUTIVE SECUR
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 273,925,315 | 7,786,089 |
Equity Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 19,000 | |
Convertible Notes Payable [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 111,743,222 | 2,389,770 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 161,984,924 | 5,192,652 |
Series C Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 3,334 | 3,334 |
Series D Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 2,500 | 2,500 |
Series E Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 191,335 | 178,833 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||||||||||
Sep. 30, 2023 | Oct. 05, 2022 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | ||||||||||||
Cash | $ 32,388 | $ 32,388 | $ 32,388 | $ 31,761 | ||||||||
Working capital | 26,300,000 | 26,300,000 | 26,300,000 | |||||||||
Net loss | 3,535,815 | $ (271,279) | $ 885,839 | $ 1,803,352 | $ (98,286) | $ 73,730 | 4,150,375 | $ 1,778,796 | ||||
Net cash used in operating activities | 655,155 | 1,355,962 | ||||||||||
Stockholders deficit | 26,315,441 | 26,315,441 | $ 22,787,224 | $ 23,092,723 | $ 21,805,438 | $ 19,993,380 | $ 25,497,550 | 26,315,441 | 21,805,438 | 22,185,550 | $ 25,105,618 | |
Accumulated deficit | $ 59,980,637 | 59,980,637 | 59,980,637 | $ 55,750,381 | ||||||||
Reverse stock split | 1-for-20 | 1-for-20 reverse stock split | ||||||||||
Increased cash flows used in operations | (655,155) | (1,355,962) | ||||||||||
Increased net cash provided by financing activities | $ 655,782 | 1,413,246 | ||||||||||
Revision of Prior Period, Adjustment [Member] | ||||||||||||
Property, Plant and Equipment [Line Items] | ||||||||||||
Net cash used in operating activities | (94,000) | |||||||||||
Increased cash flows used in operations | 94,000 | |||||||||||
Increased net cash provided by financing activities | $ 94,000 | |||||||||||
Minimum [Member] | ||||||||||||
Property, Plant and Equipment [Line Items] | ||||||||||||
Risk free interest rate | 4.13% | |||||||||||
Volatility rate | 263% | |||||||||||
Fair value assumptions, expected term | 0 years | |||||||||||
Maximum [Member] | ||||||||||||
Property, Plant and Equipment [Line Items] | ||||||||||||
Risk free interest rate | 5.55% | |||||||||||
Volatility rate | 408% | |||||||||||
Fair value assumptions, expected term | 1 year 1 month 6 days | |||||||||||
Fair Value, Inputs, Level 3 [Member] | ||||||||||||
Property, Plant and Equipment [Line Items] | ||||||||||||
Long term debt fair value | $ 4,300,000 | $ 4,300,000 | $ 4,300,000 |
PREPAID EXPENSES (Details Narra
PREPAID EXPENSES (Details Narrative) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Prepaid Expenses | ||
Prepaid expenses | $ 11,686 | $ 46,750 |
SCHEDULE OF OUTSTANDING TERM LO
SCHEDULE OF OUTSTANDING TERM LOANS (Details) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Short-Term Debt [Line Items] | ||
Notes payable | $ 10,054,677 | $ 8,041,979 |
Unamortized discounts and fees | (394,322) | (709,001) |
Loans payable | 9,660,355 | 7,332,978 |
2019 Term Loan [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable | 5,676,900 | 5,676,900 |
2022 Term Loan [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable | 3,045,634 | 2,365,079 |
2023 Term Loan [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable | $ 1,332,143 |
SCHEDULE OF CONVERTIBLE PROMISS
SCHEDULE OF CONVERTIBLE PROMISSORY NOTES (Details) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Debt Disclosure [Abstract] | ||
Convertible Notes | $ 1,168,765 | $ 1,319,024 |
Unamortized discounts | (67,328) | |
Convertible notes payable, net | $ 1,168,765 | $ 1,251,696 |
SCHEDULE OF FAIR VALUE OF DERIV
SCHEDULE OF FAIR VALUE OF DERIVATIVE LIABILITIES ESTIMATED ISSUANCE AND VALUATION MODE (Details) | Sep. 30, 2023 |
Measurement Input, Expected Dividend Rate [Member] | |
Debt Instrument [Line Items] | |
Derivative liability rate | 0 |
Measurement Input, Expected Term [Member] | Minimum [Member] | |
Debt Instrument [Line Items] | |
Term (in years) | 0 years |
Measurement Input, Expected Term [Member] | Maximum [Member] | |
Debt Instrument [Line Items] | |
Term (in years) | 1 year 1 month 6 days |
Measurement Input, Price Volatility [Member] | Minimum [Member] | |
Debt Instrument [Line Items] | |
Derivative liability rate | 178.2 |
Measurement Input, Price Volatility [Member] | Maximum [Member] | |
Debt Instrument [Line Items] | |
Derivative liability rate | 409 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | |
Debt Instrument [Line Items] | |
Derivative liability rate | 3.36 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | |
Debt Instrument [Line Items] | |
Derivative liability rate | 5.55 |
NOTES PAYABLE AND CONVERTIBLE_3
NOTES PAYABLE AND CONVERTIBLE PROMISSORY NOTES (Details Narrative) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sep. 01, 2023 USD ($) $ / shares shares | Jun. 23, 2023 USD ($) $ / shares shares | Jun. 22, 2023 USD ($) $ / shares shares | May 30, 2023 USD ($) $ / shares shares | May 10, 2023 USD ($) $ / shares shares | May 10, 2023 USD ($) $ / shares shares | Apr. 28, 2023 USD ($) $ / shares shares | Apr. 14, 2023 USD ($) $ / shares shares | Mar. 13, 2023 USD ($) | Mar. 09, 2023 USD ($) | Feb. 17, 2023 USD ($) | Feb. 16, 2023 USD ($) $ / shares shares | Feb. 03, 2023 USD ($) $ / shares shares | Feb. 01, 2023 USD ($) | Jan. 23, 2023 USD ($) | Jan. 18, 2023 USD ($) $ / shares shares | Jan. 10, 2023 USD ($) $ / shares shares | Dec. 14, 2022 USD ($) $ / shares shares | Nov. 16, 2022 $ / shares | Sep. 16, 2022 USD ($) | Jun. 27, 2022 USD ($) | May 12, 2022 USD ($) shares | May 11, 2022 USD ($) $ / shares shares | Mar. 15, 2022 USD ($) shares | Jan. 27, 2022 USD ($) $ / shares shares | Jan. 05, 2022 | Dec. 31, 2021 USD ($) | Nov. 15, 2021 | Nov. 09, 2021 | Nov. 04, 2021 shares | Oct. 07, 2021 USD ($) $ / shares shares | Oct. 04, 2021 USD ($) $ / shares shares | Aug. 17, 2021 USD ($) $ / shares shares | Aug. 11, 2021 USD ($) $ / shares shares | Jun. 25, 2021 USD ($) $ / shares shares | Apr. 12, 2021 USD ($) $ / shares shares | Jan. 31, 2021 USD ($) $ / shares shares | Oct. 30, 2020 USD ($) $ / shares shares | Jun. 26, 2020 USD ($) $ / shares | May 05, 2020 $ / shares | Feb. 05, 2020 USD ($) | Dec. 28, 2019 | Sep. 30, 2023 USD ($) $ / shares shares | Jun. 30, 2023 shares | Mar. 31, 2023 shares | Sep. 30, 2022 USD ($) | Mar. 31, 2022 shares | Sep. 30, 2023 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) shares | Dec. 31, 2019 USD ($) | Sep. 08, 2023 shares | May 11, 2023 | Jan. 02, 2022 | Nov. 30, 2021 $ / shares shares | Oct. 12, 2021 | Jul. 31, 2021 | Apr. 30, 2021 | Mar. 19, 2021 USD ($) $ / shares shares | Jan. 25, 2021 | Aug. 05, 2020 | Jun. 15, 2020 | Aug. 05, 2019 USD ($) | |
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 161,984,924 | 161,984,924 | 6,785,914 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt description | (i) the 12-month anniversary of the original issuance date of the Notes, or January 18, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. | (i) the 12-month anniversary of the original issuance date of the Notes, or December 14, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 1,245,825 | 1,265,419 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 394,322 | 394,322 | $ 709,001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan inducement fee | 809,126 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable current | 1,168,765 | 1,168,765 | 1,251,696 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding | 7,138,107 | 7,138,107 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 10,054,677 | $ 10,054,677 | 8,041,979 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cashless exercise of warrants | shares | 750,000 | 750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 12,671 | 92,068 | $ 87,921 | 306,707 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issued on convertible notes | shares | 55,317,596 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate | 18% | 16% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification of additional paid in capital to derivative liability | $ 3,462,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on fair value of derivative liabilities | (2,673,966) | (253,723) | $ (214,994) | 1,425,494 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related Party [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense related party | $ 32,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 589,458 | 589,458 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 2,133 | $ 799 | $ 756 | $ 489 | $ 489 | $ 6,586 | $ 6,161 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.0117 | $ 0.036 | $ 0.059 | $ 0.054 | $ 0.054 | $ 0.18 | $ 0.28 | $ 0.56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, amount | $ 324 | $ 5,697 | $ 9,203 | $ 6,001 | $ 21,314 | $ 10,000 | $ 3,839 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
February 16 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan inducement fee | $ 69,444 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
February 2020 Convertible Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 6,161 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 17,861 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | Convertible Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 58,055 | $ 5,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 14,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Dec. 26, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 2,641 | 2,670 | $ 7,925 | 7,925 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 52,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 5,555 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | 18% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.036 | $ 0.054 | $ 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | $ 0.40 | $ 0.00845 | $ 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | 65% | 65% | 65% | 65% | 65% | 65% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible, beneficial conversion feature | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | $ 203,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 6,900 | $ 6,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 2,133 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 2,568 | 2,568 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 210,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.0117 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cashless exercise of warrants | shares | 750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, amount | $ 324 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 58,055 | $ 58,055 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 140% | 140% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.036 | $ 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 40% premium will be recorded once a demand occurs. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 34,104 | $ 34,104 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 111,111 | $ 111,111 | $ 111,111 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 9,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 125% | 125% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.00845 | $ 0.00845 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 5,111 | 15,167 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 54,704 | $ 54,704 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 38,303 | 79,366 | 47,619 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 6,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 11 months 1 day | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 18% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 1.40 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 1.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible, beneficial conversion feature | $ 45,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | $ 69,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Threshold percentage | 70% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 57,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 15,027,929 | 15,027,929 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 262.27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 4,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | October 2020 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 1,170,913 | 1,642,202 | 1,642,202 | 251,794 | 226,882 | 64,001 | 35,816 | 11,509,337 | 11,509,337 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 52,778 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 7,204 | 7,204 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 23,568 | $ 23,568 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 35,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 37,699 | 22,619 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 11 months 19 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | 125% | 125% | 18% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 1.40 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable current | $ 47,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 27,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | $ 0.00845 | $ 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion ratio | 70 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value method | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 52,778 | $ 52,778 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 262.27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Investor and Lender [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 5,278 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 66,667 | $ 41,667 | $ 41,667 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 125% | 125% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.50 | $ 0.00845 | $ 0.00845 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 6,244 | $ 13,028 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 22,148 | $ 22,148 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 6,667 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 700,781 | 982,843 | 982,843 | 150,697 | 135,787 | 16,147 | 10,667 | 6,888,236 | 6,888,236 | 19,084 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 3,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 34,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | 18% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.78 | $ 1.50 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable current | $ 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 70% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 8,994,083 | 8,994,083 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 12,122 | $ 12,122 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issued on convertible notes | shares | 819,458 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.89 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 240.64 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | Investor [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | April 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 527,891 | 740,366 | 740,366 | 113,518 | 102,305 | 28,834 | 5,188,836 | 5,188,836 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | April 2021 [Member] | Investor [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for warrants exercise | shares | 750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | April 2021 Secured Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 1,917 | 1,812 | $ 5,687 | 7,845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price increase decrease | $ / shares | $ 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 6,025,148 | 6,025,148 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | June 2021 Secured Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 3,400 | 10,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 10,000 | 29,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note Three [Member] | June 2021 Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 50,100 | $ 50,100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 29,595 | 29,595 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
April 2021 Convertible Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for warrants exercise | shares | 7,662 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cashless exercise of warrants | shares | 12,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - June 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 66,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 421 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 3,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 21,436 | 40,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 2,377 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 15,784 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 5,040 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 9,300 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 6 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 12,721 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.78 | $ 1.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable current | $ 63,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding | $ 76,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 18,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 102,823 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 87,039 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 66,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | $ 9,300 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, amount | 9,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading securities debt | 28,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative fair value of derivative net | $ 23,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on extinguishment of debt | $ 23,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - June 2021 [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on extinguishment of debt | $ 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - June 2021 [Member] | October 4 2021 Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 14,208 | 14,208 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - August 11, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 220,500 | $ 84,805 | $ 84,805 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Sep. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.60 | $ 1.60 | $ 1.60 | $ 1.60 | $ 1.60 | 1.60 | 1.60 | $ 1.60 | $ 1.60 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 64,051 | $ 64,051 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | $ 64,305 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 10,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 40,000 | 36,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 106,505 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.036 | $ 0.054 | 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | $ 1.50 | $ 0.00845 | $ 0.00845 | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 54,278 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | 65% | 65% | 65% | 65% | 65% | 24% | 65% | 65% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | $ 0.036 | $ 0.054 | 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | 0.00845 | $ 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding | $ 210,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 128,502 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 45,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 340,893 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 234,388 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 700,781 | 982,843 | 150,697 | 135,787 | 38,303 | 21,436 | 6,888,236 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 135,695 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - August 11, 2021 [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 106,505 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - August 11, 2021 [Member] | August 11,2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.036 | $ 0.054 | 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | $ 0.00845 | $ 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 5,130 | 6,800 | $ 15,223 | 92,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 39,900 | 134,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 8,994,083 | 8,994,083 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional interest accured | $ 67,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - August 17, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 220,500 | $ 220,500 | $ 220,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 | $ 1.60 | $ 1.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 12,703 | 12,700 | $ 37,696 | 37,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 103,518 | $ 103,518 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 10,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 100,571 | 35,400 | 105,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.036 | $ 0.054 | 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | $ 1.50 | $ 0.00845 | $ 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | 65% | 65% | 65% | 65% | 65% | 65% | 65% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | $ 0.036 | $ 0.054 | 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | $ 0.00845 | $ 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding | $ 210,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 398,404 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 297,833 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 700,781 | 982,843 | 150,697 | 135,787 | 38,303 | 21,436 | 6,888,236 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - August 17, 2021 [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 36,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 100,571 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - August 17, 2021 [Member] | August 11,2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 8,994,083 | 8,994,083 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - August 17, 2021 [Member] | August 17 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.036 | $ 0.054 | 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | $ 0.00845 | $ 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - October 4, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 131,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 16% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 573 | 500 | $ 1,775 | 5,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 6,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 23,810 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 77,891 | 33,100 | 98,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 131,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 2,173 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.56 | 0.78 | $ 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | $ 2,500 | 83,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | $ 564,943 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 487,052 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | 32,109 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds form warrants | 110,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Agreegate exercise price amount | 45,238 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment fee | 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - October 4, 2021 [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | 8,905 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 31,042 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - October 4, 2021 [Member] | October 4 2021 Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 2,586 | 2,586 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 96,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note October 7, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 131,250 | 16,708 | 16,708 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 674 | 500 | 1,999 | 5,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 2,811 | 2,811 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 6,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 23,810 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 76,517 | 33,100 | 98,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.56 | 0.78 | $ 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 83,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 98,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | $ 564,184 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 487,667 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds form warrants | 110,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Agreegate exercise price amount | 45,238 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment fee | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note October 7, 2021 [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | 8,905 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 76,517 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 31,042 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - March 15, 2022 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 250,000 | 61,473 | 61,473 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 3,763 | 13,938 | 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 879 | 879 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | $ 4,191 | 31,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 180,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of debt issuance costs | 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 250,000 | 0 | 63,000 | 50,000 | 137,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | $ 30,000 | $ 32,500 | $ 15,000 | $ 10,819 | 39,285 | 43,828 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 784 | $ 76,034 | 68,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | 34,384 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aggregate guaranteed interest | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - March 15, 2022 [Member] | Investor [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 2,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - March 15, 2022 [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 162,020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.036 | $ 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Senior Secured Convertible Promissory Note One [Member] | October 2020 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | 0.036 | 0.054 | 0.054 | 0.18 | 0.279 | 0.56 | 0.78 | 0.00845 | 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | 0.036 | 0.054 | 0.054 | 0.18 | 0.279 | 0.56 | 0.78 | 0.00845 | 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Senior Secured Convertible Promissory Note Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | 0.036 | 0.18 | 0.18 | 0.18 | 0.56 | 0.78 | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Senior Secured Convertible Promissory Note Three [Member] | April 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.054 | 0.054 | 0.18 | 0.279 | 0.56 | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Convertible Promissory Note - August 11, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 1.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Convertible Promissory Note - August 17, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 1.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Convertible Promissory Note - October 4, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.18 | 0.18 | 0.18 | 0.56 | 0.00845 | 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Convertible Promissory Note October 7, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.18 | 0.18 | 0.18 | 0.279 | 0.00845 | 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | 0.0117 | 0.0117 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Senior Secured Convertible Promissory Note One [Member] | October 2020 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | $ 0.054 | $ 0.18 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | $ 0.98 | $ 0.036 | $ 0.036 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 556,171 | 780,028 | 780,028 | 119,600 | 107,767 | 30,398 | 17,012 | 5,466,813 | 5,466,813 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | $ 0.054 | $ 0.18 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | $ 0.98 | $ 0.036 | $ 0.036 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Senior Secured Convertible Promissory Note Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 1.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible note and warrant exercise price | $ / shares | 0.054 | 0.054 | 0.054 | 0.279 | 0.279 | 0.56 | 0.036 | 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Senior Secured Convertible Promissory Note Three [Member] | April 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.054 | 0.18 | 0.18 | 0.279 | 0.56 | $ 0.78 | 0.036 | 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Convertible Promissory Note - October 4, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.054 | 0.054 | 0.054 | 0.279 | 0.279 | 0.036 | 0.036 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Convertible Promissory Note October 7, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.054 | $ 0.054 | $ 0.054 | $ 0.279 | $ 0.56 | 0.036 | 0.036 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 210,000 | 180,000 | 170,000 | 120,000 | 120,000 | 155,000 | 35,716 | 17,861 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.036 | $ 0.054 | $ 0.054 | $ 0.18 | $ 0.279 | $ 0.00845 | $ 0.00845 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issued on convertible notes | shares | 1,029,458 | 660,716 | 17,861 | 12,721 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 180,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.039 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Senior Secured Convertible Promissory Note Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 6,900 | $ 6,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 2,568 | $ 2,568 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 19,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Senior Secured Convertible Promissory Note Three [Member] | April 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note - August 11, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 7,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 17,041 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note - August 17, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 5,631 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 17,209 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note - October 4, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 2,977 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 77,891 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note October 7, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 2,977 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 33,483 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note - March 15, 2022 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 3,596 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants or rights outstanding | shares | 161,984,924 | 161,984,924 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 66,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 3,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 32,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 240.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,700 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 11 months 15 days | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 11,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.92 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 247.52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.50 | $ 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 10,667 | 25,333 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 15,784 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 37,916 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 6 months 25 days | 7 months 6 days | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.81 | 0.48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 209 | 302.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - August 11, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 56,454 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.81 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 253 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - August 17, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 62,220 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 24% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.77 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 254 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - October 4, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note October 7, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 406,846 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | $ 972,000 | 972,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 564,483 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss on fair value of derivative liabilities | 214,994 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change in the fair value of derivative liabilities | 349,489 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | 0.036 | 0.054 | 0.054 | 0.18 | 0.279 | $ 0.56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Secured Convertible Promissory Note - February 2020 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 21,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 38,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 285,714 | 350,000 | 350,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 7,219 | 18,609 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 18,609 | 18,609 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 173,850 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of debt issuance costs | 26,150 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 203,000 | 51,170 | 142,386 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 85,700 | 60,625 | 60,625 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 26,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 66 months | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants maturity date | Jul. 18, 2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price increase decrease | $ / shares | $ 0.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 452,962 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.054 | 0.054 | $ 0.18 | 0.279 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | May 2022 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 277,777 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 25% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan inducement fee | 277,777 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | February 16 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 69,444 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 25% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | April 28 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 461,904 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | June 22 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 125% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt description | The Notes contain customary restrictive covenants which apply for as long as at least 75% of the Notes remain outstanding, including covenants against incurring new indebtedness or liens, repurchasing shares of common stock or common stock equivalents, paying dividends or distributions on equity securities, and transactions with affiliates, subject to certain exceptions and limitations. In addition, the SPA imposes certain additional negative covenants and obligations on the Company, including a prohibition on filing a registration statement (other than on Form S-8) unless at least 30% of the Notes have been repaid as of such filing, a prohibition on incurring new indebtedness at any time while any Notes are outstanding, and a 90-day restriction against issuing shares of common stock or common stock equivalents, subject to certain exceptions and limitations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, reduced percentage | 100% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | February 3 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 267,857 | 267,857 | 267,857 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 16,150 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | 0.036 | 0.054 | 0.054 | $ 0.18 | 0.279 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 5,536 | 14,405 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 14,405 | 14,405 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 133,850 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt description | (i) the 12-month anniversary of the original issuance date of the Notes, or February 3, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 224,000 | 56,462 | 147,292 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 64,286 | 76,714 | 76,714 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 16,100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 66 months | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants maturity date | Aug. 03, 2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price increase decrease | $ / shares | $ 0.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 424,652 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan inducement fee | $ 53,571 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | February 16 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 214,286 | 278,571 | 278,571 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 16,150 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 5,757 | 13,147 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 13,147 | 13,147 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 133,850 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt description | The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12-month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 163,646 | 41,248 | 0 | 101,775 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 45,000 | 64,286 | 61,872 | 61,872 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 61,790 | $ 16,150 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 66 months | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants maturity date | Aug. 16, 2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 339,722 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.054 | 0.054 | $ 0.18 | 0.279 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | April 28 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 285,714 | 285,714 | 285,714 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 5,905 | 9,968 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 9,968 | 9,968 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt description | (i) the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12-month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 166,364 | 41,933 | 71,104 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 85,714 | 95,261 | 95,261 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 66 months | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 452,964 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.054 | 0.054 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | June 22 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 150,000 | 150,000 | 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 3,100 | 0 | 3,400 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 3,400 | 3,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 105,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt description | (i) the 12 month anniversary of the issuance date, and (ii) the date on which the Company completes a public offering for cash of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a “national securities exchange” as defined in the Securities Exchange Act of 1934 (a “Qualified Financing”), provided that unless there is an event of default, the Company may extend the maturity date by six months in its discretion. The Notes bear interest at 8% per annum, payable monthly, subject to an increase to 15% in case of an event of default as provided for therein. Furthermore, at any time before the 12-month anniversary of the date of issuance of a Note, the Company may, after providing written notice to the holder, prepay all of the then outstanding principal amount of the Note for cash in an amount equal to the sum of 105% of the then outstanding principal amount of the Note, accrued but unpaid interest and all liquidated damages and other amounts due in respect of the Note (if any). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 106,790 | 26,917 | 29,550 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 77,240 | $ 77,240 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 66 months | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Minimum [Member] | Issuance of Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.036 | $ 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Minimum [Member] | February 3 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | 0.036 | 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Minimum [Member] | February 16 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Minimum [Member] | April 28 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Minimum [Member] | June 22 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.036 | 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Maximum [Member] | Issuance of Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Maximum [Member] | February 3 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Maximum [Member] | February 16 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Maximum [Member] | April 28 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Maximum [Member] | June 22 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.00845 | $ 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Warrant [Member] | Issuance of Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 91,100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Warrant [Member] | February 3 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 90,049 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Warrant [Member] | February 16 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 83,210 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Warrant [Member] | April 28 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 80,650 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement [Member] | Secured Convertible Promissory Note - February 2020 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - February 2020 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 550,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 18% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Aug. 05, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 381,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable current | $ 499,950 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted average percentage | 70% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock combinations | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - February 2020 [Member] | Related Party [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense related party | $ 21,038 | 21,038 | $ 62,429 | 66,846 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - February 2020 [Member] | February 2020 Convertible Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 457,359 | $ 457,359 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 140% | 140% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | $ 251,493 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 40% premium will be recorded once a demand occurs. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - February 2020 [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 53,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 322,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note - August 11, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note - August 17, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note - October 4, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 2,977 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note October 7, 2021 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt interest amount, conversion of common stock, shares | shares | 2,977 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 2,632 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Term Loan Subscription Agreements [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 5,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 707,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 12% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest during period | 15% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Jun. 28, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Public Offering Price Transaction in to Preferred Stock | 90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | $ 214,633 | 636,902 | $ 214,633 | 636,902 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 3,515,399 | 3,515,399 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 5,676,900 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt payment Interest | 3,515,399 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 142,857 | 142,857 | 142,857 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.036 | $ 0.054 | 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 2,921 | 8,627 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 9,191 | 9,191 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | 42,857 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 158,537 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 82,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of debt issuance costs | 17,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 111,523 | 28,109 | 83,413 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 42,857 | $ 22,610 | $ 22,610 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 66 months | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants maturity date | Jun. 15, 2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price increase decrease | $ / shares | $ 0.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 60% | 60% | 60% | 60% | 60% | 60% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.036 | $ 0.054 | $ 0.054 | $ 0.18 | $ 0.279 | $ 0.56 | $ 0.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.036 | $ 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | 0.036 | 0.036 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | 0.00845 | 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.00845 | $ 0.00845 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 17,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 51,066 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Holder [Member] | Term Loan Subscription Agreements [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 2,222,222 | $ 2,902,777 | $ 2,902,777 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 57,272 | 45,400 | 163,602 | 70,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accured interest | 279,651 | 279,651 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original issue discount | 222,222 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 1,111,112 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 19,231 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 1,692,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments of debt issuance costs | $ 307,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt description | (i) the 12-month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 1,693,000 | 0 | $ 562,300 | 602,979 | $ 663,300 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 222,222 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 307,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant term | 66 months | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants maturity date | Nov. 11, 2027 | Nov. 11, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price increase decrease | $ / shares | $ 0.80 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Increase in outstanding principal amount | 0 | 680,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities Purchase Agreement [Member] | Issuance of Promissory Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Increase in outstanding principal amount | 64,286 | 64,286 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities Purchase Agreement [Member] | February 16 Term Loan [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Increase in outstanding principal amount | $ 0 | $ 69,444 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities Purchase Agreement [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 11,820 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 1,151,137 |
LICENSING AGREEMENTS (Details N
LICENSING AGREEMENTS (Details Narrative) - USD ($) | 9 Months Ended | |||
Mar. 16, 2018 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Royalties due liabilities | $ 24,500 | $ 24,500 | ||
Les Laboratories Servier License Agreement [Member] | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Payments for royalties | $ 0 | $ 0 | ||
Sub-Licensing Agreement [Member] | Accrued Liabilities [Member] | ||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
Upfront payment agreement for license agreement | $ 200,000 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - Related Party [Member] - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Related Party Transaction [Line Items] | ||
Other liabilities | $ 4,392 | $ 4,392 |
Officers and Directors [Member] | ||
Related Party Transaction [Line Items] | ||
Due from related parties | $ 57,500 | $ 21,176 |
SCHEDULE OF STOCKHOLDER_ EQUITY
SCHEDULE OF STOCKHOLDER’ EQUITY NOTE, WARRANTS OR RIGHTS (Details) | Sep. 30, 2023 shares |
Warrant [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 161,984,924 |
Expiring in 2023 | 154,929 |
Expiring in 2024 | 9,058,640 |
Expiring in 2025 | 115,679,985 |
Expiring in 2026 | 31,151,420 |
Expiring in 2027 and after | 5,939,950 |
Bridge Loan [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 5,939,950 |
Expiring in 2027 and after | 5,939,950 |
Convertible Notes [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 155,873,108 |
Expiring in 2024 | 9,041,703 |
Expiring in 2025 | 115,679,985 |
Expiring in 2026 | 31,151,420 |
Other [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 17,441 |
Expiring in 2023 | 504 |
Expiring in 2024 | 16,937 |
Expiring in 2025 | |
Series F Preferred Stock [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 154,425 |
Expiring in 2023 | 154,425 |
SCHEDULE OF WARRANTS (Details)
SCHEDULE OF WARRANTS (Details) - shares | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Warrants, Beginning Balance | 6,785,914 |
Issued as a result of price adjustments on convertible notes | 55,317,596 |
Variable quantity of warrants related to the February 2020 note | 97,481,393 |
Warrants issued with 2022 Bridge Note | 4,670,301 |
Warrant cashless exercise | (750,000) |
Expirations | (1,520,280) |
Warrants, Ending Balance | 161,984,924 |
STOCKHOLDERS_ EQUITY (Details N
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | |||||||||||||||||||||||||||
Sep. 08, 2023 | Sep. 01, 2023 | Jun. 23, 2023 | May 30, 2023 | May 10, 2023 | May 10, 2023 | Apr. 28, 2023 | Apr. 14, 2023 | Jan. 10, 2023 | May 17, 2022 | May 12, 2022 | May 11, 2022 | Mar. 15, 2022 | Jan. 27, 2022 | Mar. 19, 2021 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | May 17, 2023 | Dec. 31, 2022 | Dec. 31, 2019 | Jul. 31, 2018 | Apr. 30, 2018 | Aug. 31, 2015 | Mar. 31, 2014 | |
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock, shares authorized | 100,000 | 100,000 | 100,000 | ||||||||||||||||||||||||||
Stated value per share | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||
Conversion rate per share | $ 0.006 | $ 0.006 | 0.006 | ||||||||||||||||||||||||||
Issuance of common stock with term loan | $ 34,518 | $ 60,847 | $ 5,000 | $ 27,984 | |||||||||||||||||||||||||
Loss on extinguishment of debt | $ 22,591 | ||||||||||||||||||||||||||||
Net gain on debt extinguishment | $ 12,671 | $ 92,068 | $ 87,921 | $ 306,707 | |||||||||||||||||||||||||
Issuance of common stock for convertible note conversions, shares | 55,317,596 | ||||||||||||||||||||||||||||
Removal of derivative liabilities | $ 110,512 | ||||||||||||||||||||||||||||
Cashless exercise of warrants | 750,000 | 750,000 | |||||||||||||||||||||||||||
Weighted average exercise price | $ 19.60 | ||||||||||||||||||||||||||||
Intrinsic value | $ 3,400,000 | $ 3,400,000 | |||||||||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Conversion instrument amount | $ 324 | $ 5,697 | $ 9,203 | $ 6,001 | $ 21,314 | $ 10,000 | $ 3,839 | ||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ 0.0117 | $ 0.036 | $ 0.059 | $ 0.054 | $ 0.054 | $ 0.18 | $ 0.28 | $ 0.56 | |||||||||||||||||||||
Principal amount | $ 2,133 | $ 799 | $ 756 | $ 489 | $ 489 | $ 6,586 | $ 6,161 | ||||||||||||||||||||||
February 2020 Convertible Note [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Debt conversion converted instrument shares issued | 17,861 | ||||||||||||||||||||||||||||
Issuance of common stock with term loan | $ 3,839 | ||||||||||||||||||||||||||||
Interest expense debt | 6,161 | ||||||||||||||||||||||||||||
Net gain on debt extinguishment | $ 5,000 | ||||||||||||||||||||||||||||
Secured Convertible Promissory Note Three [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Issuance of common stock for convertible note conversions, shares | 819,458 | ||||||||||||||||||||||||||||
Secured Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Conversion instrument amount | $ 324 | ||||||||||||||||||||||||||||
Debt conversion converted instrument shares issued | 210,000 | ||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ 0.0117 | ||||||||||||||||||||||||||||
Interest expense debt | $ 2,133 | ||||||||||||||||||||||||||||
Principal amount | $ 6,900 | 6,900 | |||||||||||||||||||||||||||
Interest payable current | $ 2,568 | $ 2,568 | |||||||||||||||||||||||||||
Cashless exercise of warrants | 750,000 | ||||||||||||||||||||||||||||
Secured Convertible Promissory Note [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ 0.036 | $ 0.036 | |||||||||||||||||||||||||||
Principal amount | $ 58,055 | $ 58,055 | |||||||||||||||||||||||||||
Banking Agreement [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 19,231 | 10,000 | |||||||||||||||||||||||||||
Fair value | $ 11,820 | $ 14,384 | |||||||||||||||||||||||||||
Convertible Note Investor [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 2,500 | 12,721 | |||||||||||||||||||||||||||
Issuance of common stock with term loan | $ 9,500 | ||||||||||||||||||||||||||||
Interest expense debt | 422 | ||||||||||||||||||||||||||||
Debt securities trading | 28,000 | ||||||||||||||||||||||||||||
Loss on extinguishment of debt | 18,000 | ||||||||||||||||||||||||||||
Derivative fair value net | 23,000 | ||||||||||||||||||||||||||||
Gain on extinguishment of debt | 23,000 | ||||||||||||||||||||||||||||
Net gain on extinguishment | $ 5,000 | ||||||||||||||||||||||||||||
Fair value | $ 3,596 | ||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant shares | 154,425 | 154,425 | |||||||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | $ 0.00845 | $ 0.00845 | |||||||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | 0.036 | 0.036 | |||||||||||||||||||||||||||
Series E Warrants [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Conversion instrument amount | $ 25,900 | ||||||||||||||||||||||||||||
Debt conversion converted instrument shares issued | 25,900 | ||||||||||||||||||||||||||||
Series E Warrants [Member] | Maximum [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | $ 10 | ||||||||||||||||||||||||||||
Series E Warrants [Member] | Minimum [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | $ 1 | ||||||||||||||||||||||||||||
Series E Preferred Stocks [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | $ 0.56 | $ 0.78 | |||||||||||||||||||||||||||
Conversion of shares | 3,059 | ||||||||||||||||||||||||||||
Accrued dividends | $ 5,100,000 | ||||||||||||||||||||||||||||
Accrued dividends shares | 2,035,306 | ||||||||||||||||||||||||||||
Conversion rate per share | $ 10 | ||||||||||||||||||||||||||||
Series E Preferred Stocks [Member] | Maximum [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | $ 0.56 | 0.78 | |||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Debt conversion converted instrument shares issued | 210,000 | 180,000 | 170,000 | 120,000 | 120,000 | 155,000 | 35,716 | 17,861 | |||||||||||||||||||||
Debt instrument, convertible, conversion price | $ 0.036 | $ 0.054 | $ 0.054 | $ 0.18 | $ 0.279 | $ 0.00845 | $ 0.00845 | ||||||||||||||||||||||
Issuance of common stock with term loan | $ 6,205 | $ 3,964 | $ 107 | $ 76 | |||||||||||||||||||||||||
Issuance of common stock for convertible note conversions, shares | 1,029,458 | 660,716 | 17,861 | 12,721 | |||||||||||||||||||||||||
Common Stock [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Debt conversion converted instrument shares issued | 180,000 | ||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ 0.039 | ||||||||||||||||||||||||||||
Series F Warrants [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Conversion instrument amount | $ 25,900 | ||||||||||||||||||||||||||||
Debt conversion converted instrument shares issued | 25,900 | ||||||||||||||||||||||||||||
Series F Warrants [Member] | Maximum [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | $ 0.56 | 0.78 | $ 10 | ||||||||||||||||||||||||||
Series F Warrants [Member] | Minimum [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | $ 1 | ||||||||||||||||||||||||||||
Series F Preferred Stocks [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Conversion of shares | 358 | ||||||||||||||||||||||||||||
Accrued dividends | $ 541,000 | ||||||||||||||||||||||||||||
Accrued dividends shares | 233,127 | ||||||||||||||||||||||||||||
Conversion rate per share | $ 10 | ||||||||||||||||||||||||||||
Series F Preferred Stocks [Member] | Maximum [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant exercise price shares upon conversion of debt | 0.56 | $ 0.78 | |||||||||||||||||||||||||||
Series F preferred and Accrued Dividend [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Conversion of shares | 358 | ||||||||||||||||||||||||||||
Accrued dividends | $ 543,000 | ||||||||||||||||||||||||||||
Accrued dividends shares | 233,127 | ||||||||||||||||||||||||||||
Conversion rate per share | $ 10 | ||||||||||||||||||||||||||||
Series E Preferred and Accrued Dividends [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Conversion rate per share | $ 0.56 | $ 10 | |||||||||||||||||||||||||||
Secured Convertible Promissory Note [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Debt conversion converted instrument shares issued | 300,000 | ||||||||||||||||||||||||||||
Commitment Fee [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Stock repurchased during period, shares | 5,954 | ||||||||||||||||||||||||||||
Commitment fee | $ 2,000 | ||||||||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant shares | 161,984,924 | 161,984,924 | |||||||||||||||||||||||||||
Weighted average exercise price | $ 0.015 | $ 0.015 | |||||||||||||||||||||||||||
Adjustable warrants | 155,825,488 | 155,825,488 | |||||||||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock designated shares | 1,000 | 1,000 | |||||||||||||||||||||||||||
Series A Junior Participating Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock designated shares | 90,000 | 90,000 | |||||||||||||||||||||||||||
Series C Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock, shares authorized | 1,200 | 1,200 | 1,200 | ||||||||||||||||||||||||||
Preferred stock designated shares | 1,200 | ||||||||||||||||||||||||||||
Stated value per share | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ 510,000 | $ 510,000 | $ 510,000 | ||||||||||||||||||||||||||
Preferred stock, shares outstanding | 100 | 100 | 100 | ||||||||||||||||||||||||||
Preferred stock shares issued | 100 | 100 | 100 | ||||||||||||||||||||||||||
Series D Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock, shares authorized | 220 | 220 | 220 | ||||||||||||||||||||||||||
Preferred stock designated shares | 220 | ||||||||||||||||||||||||||||
Stated value per share | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ 12,000 | $ 12,000 | $ 12,000 | ||||||||||||||||||||||||||
Preferred stock, shares outstanding | 40 | 40 | 40 | ||||||||||||||||||||||||||
Preferred stock shares issued | 40 | 40 | 40 | ||||||||||||||||||||||||||
Series E Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock, shares authorized | 3,500 | 3,500 | 3,500 | ||||||||||||||||||||||||||
Preferred stock designated shares | 3,500 | ||||||||||||||||||||||||||||
Stated value per share | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ 1,886,414 | $ 1,886,414 | $ 1,886,414 | ||||||||||||||||||||||||||
Preferred stock, shares outstanding | 267 | 267 | 267 | ||||||||||||||||||||||||||
Preferred stock shares issued | 267 | 267 | 267 | ||||||||||||||||||||||||||
Series F Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock, shares authorized | 2,200 | 2,200 | 2,200 | ||||||||||||||||||||||||||
Preferred stock designated shares | 2,200 | ||||||||||||||||||||||||||||
Stated value per share | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | 0 | ||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 0 | ||||||||||||||||||||||||||
Series G Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock, shares authorized | 6,000 | 6,000 | 6,000 | ||||||||||||||||||||||||||
Preferred stock designated shares | 6,000 | ||||||||||||||||||||||||||||
Stated value per share | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | 0 | ||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 0 | ||||||||||||||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Stated value per share | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ 5,100 | ||||||||||||||||||||||||||||
Preferred Stock, Voting Rights | voting rights of 33.33 votes | ||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ 150 | $ 150 | |||||||||||||||||||||||||||
Preferred stock, shares outstanding | 100 | 100 | |||||||||||||||||||||||||||
Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Stated value per share | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ 300 | $ 300 | |||||||||||||||||||||||||||
Preferred Stock, Voting Rights | voting rights of 62.5 votes | ||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ 80 | $ 80 | |||||||||||||||||||||||||||
Preferred stock, shares outstanding | 40 | 40 | |||||||||||||||||||||||||||
Preferred stock stated dividend rate | 5% | ||||||||||||||||||||||||||||
Series E Convertible Preferred Stock and Warrants [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Stated value per share | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ 10 | $ 10 | |||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | ||||||||||||||||||||||||||||
Antidilution price protection | Feb. 10, 2020 | ||||||||||||||||||||||||||||
Series E Preferred Stocks [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 267 | 267 | |||||||||||||||||||||||||||
Accrued dividends | $ 578,333 | $ 578,333 | |||||||||||||||||||||||||||
Warrant shares | 1,453,028 | ||||||||||||||||||||||||||||
Series F Convertible Preferred Stock and Warrants [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Stated value per share | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ 10 | $ 10 | |||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | ||||||||||||||||||||||||||||
Antidilution price protection | Feb. 10, 2020 | ||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Warrant shares | 154,425 | 154,425 | |||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 0 | ||||||||||||||||||||||||||
Series G Convertible Preferred Shares [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Stated value per share | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ 10 | $ 10 | |||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | ||||||||||||||||||||||||||||
Series G Preferred Stock [Member] | |||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 0 |
SCHEDULE OF SHARE BASED PAYMENT
SCHEDULE OF SHARE BASED PAYMENTS ARRANGEMENT, OPTION ACTIVITY (Details) | 9 Months Ended |
Sep. 30, 2023 $ / shares shares | |
Share-Based Payment Arrangement [Abstract] | |
Options Outstanding Beginning | shares | 19,000 |
Options Outstanding, Weighted Average Exercise Price, Beginning | $ / shares | $ 19.60 |
Options expired / forfeited | shares | (19,000) |
Options expired/forfeited, Weighted Average Exercise Price | $ / shares | $ 19.60 |
Options Outstanding Ending | shares | |
Options Outstanding, Weighted Average Exercise Price, Ending | $ / shares | |
Options Exercisable | shares | |
Exercisable, Weighted Average Exercise Price | $ / shares |
STOCK INCENTIVE PLANS (Details
STOCK INCENTIVE PLANS (Details Narrative) | 9 Months Ended |
Sep. 30, 2023 shares | |
Share-Based Payment Arrangement [Abstract] | |
Shares granted | 0 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 1 Months Ended | ||||||||
Feb. 01, 2023 | Jul. 20, 2022 | Jul. 18, 2022 | Nov. 17, 2021 | Aug. 20, 2021 | Jul. 28, 2021 | Feb. 16, 2022 | Sep. 30, 2023 | Dec. 31, 2022 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Contract liabilities | $ 100,000 | ||||||||
Licensing Agreement MLR1019 [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Debt instrument cash payments | $ 21,800,000 | ||||||||
Gross sales percentage | 5% | ||||||||
Option purchase percentage | 10% | ||||||||
Royalty gross sales percentage | 2.50% | ||||||||
Licensing Agreement - MLR 1023 [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
License agreement commitments description | On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising | if the Company failed to raise $4.0 million within 120 days of the effective date of the agreement then the MLR-1023 Agreement would immediately terminate unless, by 120 days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 days would be provided to allow for the completion of the raise (the “Raise Requirement”). | the Company to raise $4 million (the “Raise Requirement”) to June 16, 2022. | ||||||
Licensing Agreement [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Payment for licensing agreement | $ 136,921 | $ 136,921 | |||||||
Capital raise in additional | $ 500,000 | $ 500,000 | |||||||
Licensing Agreement [Member] | Chief Scientific Officer [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Capital raise in additional | $ 500,000 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | 2 Months Ended | ||||||||||
Oct. 02, 2023 | Sep. 01, 2023 | Jun. 23, 2023 | May 30, 2023 | May 10, 2023 | May 10, 2023 | Apr. 28, 2023 | Apr. 14, 2023 | Jan. 10, 2023 | Nov. 17, 2023 | Sep. 30, 2023 | |
Subsequent Event [Line Items] | |||||||||||
Cashless exercise of warrants | 750,000 | ||||||||||
Common Stock [Member] | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Convertible note shares | 210,000 | 180,000 | 170,000 | 120,000 | 120,000 | 155,000 | 35,716 | 17,861 | |||
Convertible Debt [Member] | Common Stock [Member] | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Convertible note shares | 180,000 | ||||||||||
Subsequent Event [Member] | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Shares issued for warrants exercise | 300,000 | ||||||||||
Cashless exercise of warrants | 750,000 | ||||||||||
Subsequent Event [Member] | Common Stock [Member] | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Convertible note shares | 1,751,988 | ||||||||||
Subsequent Event [Member] | Convertible Debt [Member] | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Convertible note principal | $ 20,749 | ||||||||||
Convertible note interest | $ 3,654 |